Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Teresa López‐Fernández, Daniel J. Lenihan et al.|European Journal of Heart Failure|2020Cited by 767
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studyAytug Kizilors, Hugues de Lavallade, Elena Crisà et al.|The Lancet Haematology|2019Cited by 56